Brief: Ryvu Announces Partial Clinical Hold Of Phase Ib Clinical Trial Of RVU120
April 8 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* RYVU ANNOUNCES PARTIAL CLINICAL HOLD OF PHASE IB CLINICAL
TRIAL
OF RVU120 (SEL120) IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC
SYNDROME
* RYVU THERAPEUTICS - PARTIAL CLINICAL HOLD INITIATED AFTER
RECENT
REPORT TO FDA OF ADVERSE EVENT INVOLVING PATIENT DEATH POSSIBLY
RELATED TO RVU120
Source text for Eikon: ID:nPng9xfJa
Further company coverage: RVU.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys